Eli Lilly Launches Website for Community Oncologists

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 2
Volume 10
Issue 2

INDIANAPOLIS-Eli Lilly and Company has launched a new website for community medical oncologists and their staffs. The site, located at www.lillydirect.com, is designed to save oncology health care professionals time by streamlining many of their business-related responsibilities.

INDIANAPOLIS—Eli Lilly and Company has launched a new website for community medical oncologists and their staffs. The site, located at www.lillydirect.com, is designed to save oncology health care professionals time by streamlining many of their business-related responsibilities.

For example, using the new website, physicians can access several major wholesale distributors of oncology products at one time to place orders for chemotherapeutic agents.

Other features of the website include reimbursement assistance, patient messaging, medical information on Lilly oncology products, and links to information on Lilly and non-Lilly oncology clinical trials, publications, scientific meetings, and cooperative groups and associations.

Articles in this issue
Activated T Cells Can Alter Behavior of Leukemic B Cells
Response Continues for at Least 8 Months with Ibritumomab Tiuxetan
Chemotherapy Without Methotrexate Achieves Superb Results in Children With NHL
Iodine I 131 Tositumomab Induces Response in 70% of Patients Progressing After Rituximab
Synthetic Anthracycline Produces High Response Rates in SCLC
Ibritumomab Tiuxetan Produces 73% Response Rate in B-cell NHL
Rituximab Produces Clinical Responses in Even Steroid-Refractory Idiopathic Thrombocytopenic Purpura
G-CSF Might Prolong Rituximab Responses in NHL
Use of CAD Increases the Early Detection of Breast Cancer by 20%
Rituximab Plus Fludarabine May Be Good Alternative to Rituximab Plus CHOP
Student Cigarette Smoking Falls Significantly
Injectable COX-2 Inhibitor Effective in Postsurgery Pain
Patients’ Exercise Needs May Differ After Cancer Therapy
HAART Improves Survival in HIV-Positive NHL Patients
Liposomal Tretinoin Produces Impressive Responses in Refractory B-cell and T-cell Lymphomas
Recent Videos
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
5 experts are featured in this series
2 experts are featured in this series.
5 experts are featured in this series
2 experts are featured in this series.
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
Related Content
13 Preliminary Analysis of Change During Treatment of Financial Toxicity and Quality of Life in Breast Cancer Patients

13 Preliminary Analysis of Change During Treatment of Financial Toxicity and Quality of Life in Breast Cancer Patients

Amanda Reynolds;Jonathan Klein;Joshua Feinberg;Bayle Smith-Salzberg;Pasang Sherpa;Vijaya Natarajan;Fleure Gallant;Ashley Anderson;Mukuhi Ng’ang’a
July 4th 2025
Article
Unveiling Advances in GU Cancers: Insights from Oncology Decoded

Unveiling Advances in GU Cancers: Insights from Oncology Decoded

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;John Burke, MD;Dhaval R. Shah, MBBS
July 3rd 2025
Podcast

Dive into the latest in genitourinary oncology with "Oncology Decoded," featuring discussions on KEYNOTE-564 with RCC.

Experts discussed diagnosing and treating epithelioid sarcoma, emphasizing the importance of clinical history and the role of multiple multidisciplinary clinicians in care.

Diagnosing and Treating Patients With Epithelioid Sarcoma

ONCOLOGY Staff
July 4th 2025
Article

Experts discussed diagnosing and treating epithelioid sarcoma, emphasizing the importance of clinical history and the role of multiple multidisciplinary clinicians in care.

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Benjamin J. Golas, MD
June 30th 2025
Podcast

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Busulfan/melphalan elicited higher PFS among patients with ISS2 or ISS3 disease, and melphalan-200 improved PFS in ISS1 disease.

Busulfan-Enhanced VRD Regimen Improves Efficacy in NDMM

Roman Fabbricatore
July 3rd 2025
Article

Busulfan/melphalan elicited higher PFS among patients with ISS2 or ISS3 disease, and melphalan-200 improved PFS in ISS1 disease.

Investigators will present detailed results from the phase 3 FORTITUDE-101 trial at a future medical meeting.

Bemarituzumab Regimen Improves Survival in FGFR2b+ Gastric/GEJ Cancer

Russ Conroy
July 3rd 2025
Article

Investigators will present detailed results from the phase 3 FORTITUDE-101 trial at a future medical meeting.